Cadila Healthcare launch pipeline points to healthy outlook, stock gains

Strong Q4, healthy forecast could result in more upside for stock

The stock of Cadila Healthcare gained 7 per cent after the company reported better-than-expected March quarter (Q4) results. This was on the back of strong generic sales of limited-competition ulcerative colitis drug Lialda and anti-infective Tamiflu in the US market. The 29 per cent jump in overall sales was largely on account of its performance in the US market, where sales were up 66 per cent over the year-ago quarter. Given the high-margin products and limited price erosion in the US, operating profit margins also improved 870 basis points (bps) to 25.8 per cent.